Inhibition of chemical cautery-induced corneal neovascularization by topical pigment epithelium-derived factor eyedrops

Cornea

Volumn 29, Issue 9, 2010, Pages 1055-1061

  Jin, Ji ^a   Ma, Jian Xing ^b   Guan, Ming ^c   Yao, Ke ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c FUDAN UNIVERSITY   (China)

Author keywords

angiogenesis; cornea; endothelial cell; NV; pigment epithelium derived factor; VEGF

Indexed keywords

CD34 ANTIBODY; CHLORAMPHENICOL; CHONDROITIN SULFATE; PIGMENT EPITHELIUM DERIVED FACTOR; SILVER NITRATE; VASCULOTROPIN; CD34 ANTIGEN; EYE PROTEIN; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; RECOMBINANT PROTEIN; SERINE PROTEINASE INHIBITOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; CAUTERIZATION; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING; ANIMAL; CHEMICALLY INDUCED; CORNEAL NEOVASCULARIZATION; DISEASE MODEL; METABOLISM; SPRAGUE DAWLEY RAT; TOPICAL DRUG ADMINISTRATION; TOXICITY;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIGENS, CD34; BLOTTING, WESTERN; CAUTERY; CHLORAMPHENICOL; CHONDROITIN SULFATES; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; EYE PROTEINS; IMMUNOHISTOCHEMISTRY; MALE; NERVE GROWTH FACTORS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SERPINS; SILVER NITRATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77956227620     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3181cc7987     Document Type: Article

References (31)

1. Klintworth GK. Corneal Angiogenesis. A Comprehensive and Critical Review. Berlin, Germany: Springer; 1991.
2. Peyman GA, Kivilcim M, Morales AM, et al. Inhibition of corneal angiogenesis by ascorbic acid in the rat model. Graefes Arch Clin Exp Ophthalmol. 2007;245:1461-1467.
3. Hill JC, Maske R. An animal model for corneal graft rejection in high-risk keratoplasty. Transplantation. 1988;46:26-30.
4. Zhang SX, Ma JX. Ocular NV. Implication of endogenous angio-genic inhibitors and potential therapy. Prog Retin Eye Res. 2007;26: 1-37.
5. Kvanta A. Ocular angiogenesis: the role of growth factors. Acta Ophthalmol Scand. 2006;84:282-288.
6. Dorrell M, Usitalo-Jarvinen H, Aguilar E, et al. Ocular neovasculariza-tion: basic mechanisms and therapeutic advances. Surv Ophthalmol. 2007;52(Suppl):S3-S19.
7. Jimenez B, Volpert OV. Mechanistic insights on the inhibition of tumor angiogenesis. J Mol Med. 2001;78:663-672.
8. Miller JW. Vascular endothelial growth factor and ocular neovasculariza-tion. Am J Pathol. 1997;151:13-23.
9. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. 1999;285: 245-248.
10. Gao GQ, Li Y, Ma JX, et al. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett. 2001;489: 270-276.
11. Spranger J, Osterhoff M, Reimann M, et al. Loss of the antiangiogenic PEDF in patients with angiogenic eye disease. Diabetes. 2001;50:2641-2645.
12. Jin J, Guan M, Jian-xing Ma, et al. Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea. 2003;22:473-477.
13. Damico FM. Angiogenesis and retinal diseases. Arq Bras Oftalmol. 2007; 70:547-553.
14. Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006;104:264-302.
15. Ogata N, Wada M, Otsuji T, et al. Expression of pigment epithelium-derived factor in normal adult rat eye and experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2002;43:1168-1175.
16. Holzer MP, Solomon KD, Vroman DT, et al. Photodynamic therapy with verteporfin in a rabbit model of corneal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:2954-2958.
17. Epstein RJ, Hendricks RL, Harris DM. Photodynamic therapy for corneal neovascularization. Cornea. 1991;10:424-432.
18. Chang JH, Gabison EE, Kato T, et al. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12:242-249.
19. Senger DR. Vascular permeability factor VPF, VEGF in tumor biology. Cancer Metastasis Rev. 1993;12:303-324.
20. Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound and inflammation-related corneal neovasculariza-tion. Invest Ophthalmol Vis Sci. 1998;39:18-22.
21. Sekiyama E, Nakamura T, Kawasaki S, et al. Different expression of angiogenesis-related factors between human cultivated corneal and oral epithelial sheets. Exp Eye Res. 2006;83:741-746.
22. Petersen SV, Valnickova Z, Enghild JJ. Pigment-epithelium-derived factor (PEDF) occurs at a physiologically relevant concentration in human blood: purification and characterization. Biochem J. 2003;374:199-206.
23. Takenaka K, Yamagishi S, Jinnouchi Y, et al. Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells. Life Sci. 2005;77:3231-3241.
24. Cursiefen C, Hofmann-Rummelt C, Kuchle M, et al. VEGF-immunoac-tivity in human corneal buttons with neovascularization. Invest Ophthalmol Vis Sci. 1998;39:3418-3444.
25. Van Setten GB. VEGF in normal human cornal epithelium: detection and physiological importance. Acta Ophthalmol Scand. 1997;75:649-652.
26. Karakousis PC, John SK, Behling KC, et al. Localization of PEDF in developing and adult human ocular tissues. Mol Vis. 2001;7:154-163.
27. Stellmach V, Crawford SE, Zhou W, et al. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent PEDF. Proc Natl Acad Sci\USA. 2001;98:2593-2597.
28. Tong JX, Yao YF. Contribution of VEGF and PEDF to choroidal angio-genesis: a need for balanced expressions. Clin Biochem. 2006;39:267-276.
29. Zhang SX, Wang JJ, Ma JX, et al. Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol. 2006;37:1-12.
30. Middleton J, Americh L, Gayon R, et al. A comparative study of endothelial cell markers expressed in chronically inflamed human tissues: MECA-79, Duffy antigen receptor for chemokines, von Willebrand factor, CD31, CD34, CD105 and CD146. J Pathol. 2005;206:260-268.
31. Lin G, Finger E, Gutierrez-Ramos JC. Expression of CD34 in endothelial cells, hematopoietic progenitors and nervous cells in fetal and adult mouse tissues. Eur J Immunol. 1995;25:1508-1516.